Furthermore, we explored the molecular mechanism involved in inhibition of CDH13 in imatinib-resistant CML cell growth, providing a new strategy to overcome resistance to imatinib-independent BCR-ABL1. This evidence concerns the gene CDH13 and chronic myelogenous leukemia, BCR-ABL1 positive.